Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(11 sites)
Belgium
Institut Jules Bordet, Anderlecht Antwerp University Hospital, Edegem France
Hopital Saint Joseph, Paris Centre Eugène Marquis, Rennes Institut de Cancerologie de l'Ouest, Saint-Herblain Institut Gustave Roussy, Villejuif Spain
University Hospital A Coruña Biomedical Research Institute (INIBIC), A Coruña Institut d'Investigació Biomèdica de Girona Dr. Josep Trueta (IDIBGI), Girona Hospital Regional Universitario de Málaga, Málaga